ASP8477

ASP8477 is a potent, selective, and orally active small molecule inhibitor of fatty acid amide hydrolase (FAAH), an enzyme responsible for the degradation of endocannabinoids such as anandamide. By inhibiting FAAH, ASP8477 increases levels of endogenous cannabinoids in the brain and plasma, which can modulate pain signaling pathways. It was developed by Astellas Pharma for the treatment of neuropathic pain conditions including painful diabetic peripheral neuropathy and postherpetic neuralgia. Preclinical studies demonstrated analgesic effects in animal models without significant central nervous system side effects or motor impairment. Clinical trials reached phase 2 but did not demonstrate significant efficacy over placebo in patients with peripheral neuropathic pain, leading to discontinuation of its development[1][3][4][6].